Cargando…

Inhibition of Chk1 by miR-320c increases oxaliplatin responsiveness in triple-negative breast cancer

Checkpoint kinase 1 (Chk1) expression is enhanced in most cancers owing to oncogenic activation and constant replicative stress. Chk1 inactivation is a promising cancer therapy, as its inactivation leads to genomic instability, chromosomal catastrophe, and cancer cell death. Herein, we observed that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Sera, Kim, Yesol, Lee, Soo-Been, Kang, Hyeok-Gu, Kim, Da-Hyun, Park, Jee Won, Chung, Daeun, Kong, Hyunkyung, Yoo, Kyung Hyun, Kim, Yonghwan, Han, Wonshik, Chun, Kyung-Hee, Park, Jong Hoon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548284/ https://www.ncbi.nlm.nih.gov/pubmed/33041328 http://dx.doi.org/10.1038/s41389-020-00275-x

Ejemplares similares

Reduced miR-371b-5p expression drives tumor progression via CSDE1/RAC1 regulation in triple-negative breast cancer
por: Kim, Yesol, et al.
Publicado: (2022)

Autophagy inhibits cancer stemness in triple‐negative breast cancer via miR‐181a‐mediated regulation of ATG5 and/or ATG2B
por: Park, Jee Won, et al.
Publicado: (2022)

Characterization of a Novel Gene in the Extended MHC Region of Mouse, NG29/Cd320, a Homolog of the Human CD320
por: Park, Hyo Jin, et al.
Publicado: (2009)

Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing
por: Yoo, Tae-Kyung, et al.
Publicado: (2022)

CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer
por: Hsieh, Chi-Che, et al.
Publicado: (2022)

Checkpoint Kinase 1 (CHK1) Inhibition Enhances the Sensitivity of Triple-Negative Breast Cancer Cells to Proton Irradiation via Rad51 Downregulation
por: Choi, Changhoon, et al.
Publicado: (2020)

ATM/CHK/p53 Pathway Dependent Chemopreventive and Therapeutic Activity on Lung Cancer by Pterostilbene
por: Lee, Hani, et al.
Publicado: (2016)

Oxaliplatin-Induced Immune-Mediated Thrombocytopenia: A Case Report
por: Woo, Hyun Sun, et al.
Publicado: (2015)

Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis
por: Keam, Bhumsuk, et al.
Publicado: (2011)

A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma
por: Lee, Dae-Won, et al.
Publicado: (2018)

Location of Triple-Negative Breast Cancers: Comparison with Estrogen Receptor-Positive Breast Cancers on MR Imaging
por: Kim, Won Hwa, et al.
Publicado: (2015)

The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer
por: Rhee, Jiyoung, et al.
Publicado: (2008)

Zingiber officinale Roscoe Rhizomes Attenuate Oxaliplatin-Induced Neuropathic Pain in Mice
por: Lee, Ji Hwan, et al.
Publicado: (2021)

CHK2 is involved in the p53-independent radiosensitizing effects of valproic acid
por: Choo, Dong Wan, et al.
Publicado: (2017)

Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2020)

A Multicenter Phase II Trial of Gemcitabine Plus Oxaliplatin in Unresectable Gallbladder Cancer
por: Woo, Sang Myung, et al.
Publicado: (2013)

Epigenetic Upregulation of MAGE-A Isoforms Promotes Breast Cancer Cell Aggressiveness
por: Oh, Chaeun, et al.
Publicado: (2021)

Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer
por: Keam, Bhumsuk, et al.
Publicado: (2007)

S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial
por: Kim, Seung Tae, et al.
Publicado: (2014)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer
por: Lee, Hee Jun, et al.
Publicado: (2013)

Oxaliplatin-Induced Chronic Peripheral Neurotoxicity: A Prospective Analysis in Patients with Colorectal Cancer
por: Baek, Kyung Kee, et al.
Publicado: (2010)

MRI Radiomic Features: Association with Disease-Free Survival in Patients with Triple-Negative Breast Cancer
por: Kim, Sungwon, et al.
Publicado: (2020)

Effects of Contrast Therapy Using Infrared and Cryotherapy as Compared with Contrast Bath Therapy on Blood Flow, Muscle Tone, and Pain Threshold in Young Healthy Adults
por: Kim, JinHong, et al.
Publicado: (2020)

PAK6 promotes homologous-recombination to enhance chemoresistance to oxaliplatin through ATR/CHK1 signaling in gastric cancer
por: Huang, Weicai, et al.
Publicado: (2022)

A Muti-center, Randomized Phase II Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer
por: Kim, Jung Han, et al.
Publicado: (2015)

A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy
por: Kim, Su-Hyun, et al.
Publicado: (2018)

A Phase II Trial of S-1 and Oxaliplatin in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane (KCSG-BR07-03)
por: Lee, Dae-Won, et al.
Publicado: (2023)

Antiproliferative Activity of Krukovine by Regulating Transmembrane Protein 139 (TMEM139) in Oxaliplatin-Resistant Pancreatic Cancer Cells
por: Lee, Jee-Hyung, et al.
Publicado: (2023)

A novel miR-34a target, protein kinase D1, stimulates cancer stemness and drug resistance through GSK3/β-catenin signaling in breast cancer
por: Kim, Do Yeon, et al.
Publicado: (2016)

PKR-Mediated Phosphorylation of eIF2a and CHK1 Is Associated with Doxorubicin-Mediated Apoptosis in HCC1143 Triple-Negative Breast Cancer Cells
por: Lee, Sol, et al.
Publicado: (2022)

320 Development of a Questionnaire for the Assessment of Bronchial Hyperresponsiveness in Korea
por: Lim, Seong Yong, et al.
Publicado: (2012)

A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1
por: Kim, Kwang Seok, et al.
Publicado: (2016)

Cannabidiol Overcomes Oxaliplatin Resistance by Enhancing NOS3- and SOD2-Induced Autophagy in Human Colorectal Cancer Cells
por: Jeong, Soyeon, et al.
Publicado: (2019)

Pharmacokinetic Profile and Anti-Adhesive Effect of Oxaliplatin-PLGA Microparticle-Loaded Hydrogels in Rats for Colorectal Cancer Treatment
por: Abuzar, Sharif Md, et al.
Publicado: (2019)

Genipin increases oxaliplatin-induced cell death through autophagy in gastric cancer
por: Kim, Bo Ram, et al.
Publicado: (2020)

Long-term Efficacy of S-1 Monotherapy or Capecitabine Plus Oxaliplatin as Adjuvant Chemotherapy for Patients with Stage II or III Gastric Cancer after Curative Gastrectomy: a Propensity Score-Matched Multicenter Cohort Study
por: Lee, Chang Min, et al.
Publicado: (2020)

Long-Term Survival Outcomes of Elderly Patients Treated With S-1 or Capecitabine Plus Oxaliplatin for Stage II or III Gastric Cancer: A Multicenter Cohort Study
por: Choi, Seohee, et al.
Publicado: (2022)

Sarcoidosis Associated with Oxaliplatin-Based Chemotherapy for Colorectal Cancer
por: Choi, Ji Hoon, et al.
Publicado: (2014)

The double face of miR-320: cardiomyocytes-derived miR-320 deteriorated while fibroblasts-derived miR-320 protected against heart failure induced by transverse aortic constriction
por: Zhang, Xudong, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_g260qcrvrm37mlg6lvk56ri2it